ATH Alterity Therapeutics Ltd
- 0.006
- 0.0000.00%
Alterity Therapeutics Ltd News
Press Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund MELBOURNE, Australia and SAN FRANCISCO, March 27, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (AS
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
Alterity Therapeutics (ASX:ATH) received a AU$3.9 million research and development tax incentive refund for eligible activities for the year ended June 30, 2023. The rebate will be used for clinical t
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
Alterity Therapeutics (ASX:ATH) secured binding commitments to raise about AU$3.3 million via a share placement priced at AU$0.0038 apiece. Proceeds will fund the biotechnology company's clinical tria
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation
Alterity Therapeutics (ASX:ATH) advanced its phase two trial evaluating the use of the ATH434-201 medication in patients with an early onset of multiple system atrophy. The move was made following rec
Alterity Therapeutics Completes Securities Purchase Plan
Alterity Therapeutics (ASX:ATH) completed a securities purchase plan that raised AU$2 million, the biotechnology company said Friday. The company said that about AU$577,000 in excess subscriptions wer
Alterity Dispatches Documents Of Planned Share Sale
Alterity Therapeutics (ASX:ATH) said offer documents pertaining to the firm's securities purchase plan (SPP), approved by shareholders on Dec. 29, 2023, have been mailed to eligible equity holders. Th
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%
Alterity Therapeutics (ASX:ATH) completed the second tranche of an AU$4.8 million placement to Australian and global institutions and other unrelated sophisticated, professional, or other exempt inves
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan
Alterity Therapeutics (ASX:ATH) will open on Jan. 10, 2024, a share purchase plan to raise up to AU$2 million. The purchase plan will close Jan. 25, 2024, according to a Friday news release. Shares un
Alterity: Hains Follows Resignation of Kathryn Andrews, CFO Since 2014 >ATHE
Alterity: Hains Follows Resignation of Kathryn Andrews, CFO Since 2014 >ATHE
Alterity: Andrews to Support Company During Transition>ATHE
Alterity: Andrews to Support Company During Transition>ATHE
Alterity: CFO Appointment Effective Jan 31, 2024 >ATHE
Alterity: CFO Appointment Effective Jan 31, 2024 >ATHE
Press Release: Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer MELBOURNE, Australia and SAN FRANCISCO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alte
Alterity Therapeutics Shares Up Fivefold on New Parkinson's Drug Data
By Dean Seal Shares of Alterity Therapeutics quintupled after the company disclosed promising new data on the effect of its Parkinson's disease treatment in monkeys. The stock hit $8.50 in premarket
ADRs Close Lower; Alterity Therapeutics Ltd. Declines 30.3%
This article was automatically generated by MarketWatch using technology from Automated Insights. International stocks trading in New York closed lower on Wednesday, as the S&P/BNY Mellon index of Am
Alterity Therapeutics ADRs Shares Dive 31% on Raised Capital
By Denny Jacob American depositary receipts of Alterity Therapeutics dived 31% to $1.64 following the raising of capital to provide ongoing funding to clinical trials. ADRs are down 53% on the year
Alterity Therapeutics Raises AU$4.8 Million Via Share Placement
Alterity Therapeutics (ASX:ATH) raised AU$4.8 million via a placement priced at AU$0.0035 per share. Proceeds will mainly be used to advance ongoing phase two clinical trials in multiple system atroph
Alterity Therapeutics Completes Recruitment for Phase Two Multiple System Atrophy Trial
Alterity Therapeutics (ASX:ATH) completed the recruitment of 77 patients for its phase two trial investigating the safety, tolerability, and efficacy of the oral therapy agent ATH434-201 in patients w
Alterity Therapeutics Ltd Files For Mixed Shelf Of Up To $50M
Alterity Therapeutics Ltd Files For Mixed Shelf Of Up To $50M
Press Release: Alterity Therapeutics Receives a $4.74 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Receives a $4.74 million Research & Development Tax Incentive Refund MELBOURNE, Australia and SAN FRANCISCO, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics Limited (ASX
Analysis
Price Target
No Data
